Therapeutic Guide for mTOuRing through the Braided Kidney Cancer Genomic River

Area of Science:

• Oncology
• Genomics
• Cancer Biology

Background:

• mTORC1 inhibitors are approved for metastatic kidney cancer.
• Patient response to these inhibitors is highly variable.
• Understanding this heterogeneity is crucial for improving treatment outcomes.

Purpose of the Study:

• To investigate the genomic underpinnings of heterogeneous responses to mTORC1 inhibitors in kidney cancer.
• To explore convergent evolution of cancer pathways in therapeutic outliers.
• To identify novel therapeutic targets and strategies for kidney cancer.

Main Methods:

• Case-based cancer genomic sequencing of patients with metastatic kidney cancer treated with mTORC1 inhibitors.
• Analysis of therapeutic outliers (both responders and non-responders).
• Comparative genomic analysis to identify common and distinct evolutionary patterns.

Main Results:

• Observed significant heterogeneity in treatment benefit among patients.
• Identified convergent evolution of cancer pathways, suggesting complex biological mechanisms.
• Genomic profiling revealed patterns beyond individual gene mutations driving treatment response.

Conclusions:

• Genomic sequencing of outliers is valuable for understanding complex cancer evolution.
• Convergent pathway evolution contributes to heterogeneous responses to mTORC1 inhibitors.
• Future research should focus on these complex pathways for improved kidney cancer therapies.